摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(吡咯烷-1-基磺酰基)乙胺盐酸盐 | 31644-52-7

中文名称
2-(吡咯烷-1-基磺酰基)乙胺盐酸盐
中文别名
——
英文名称
2-(pyrrolidin-1-ylsulfonyl)ethanamine
英文别名
2-pyrrolidin-1-ylsulfonylethanamine
2-(吡咯烷-1-基磺酰基)乙胺盐酸盐化学式
CAS
31644-52-7
化学式
C6H14N2O2S
mdl
MFCD06801273
分子量
178.255
InChiKey
JRFULQLOOJLLNB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    308.9±44.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    71.8
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and biological properties of new 1β-methylcarbapenems
    摘要:
    The synthesis and biological activity of the novel series of 1 beta-methylcarbapenems, 1 and 2 were described. Most compounds displayed high potent antibacterial activity. The best compound in this series, 2a (IH201; R-2=NH2) showed an excellent and a broad spectrum as well as high renal DHP-I stability. It also possessed good in vivo efficacy and high safety. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(98)00270-4
  • 作为产物:
    参考文献:
    名称:
    Synthesis and biological properties of new 1β-methylcarbapenems
    摘要:
    The synthesis and biological activity of the novel series of 1 beta-methylcarbapenems, 1 and 2 were described. Most compounds displayed high potent antibacterial activity. The best compound in this series, 2a (IH201; R-2=NH2) showed an excellent and a broad spectrum as well as high renal DHP-I stability. It also possessed good in vivo efficacy and high safety. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(98)00270-4
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES OU INFLAMMATOIRES OU DE CANCERS
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2018041964A1
    公开(公告)日:2018-03-08
    Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.
    化合物的化学式(I)及其盐:其中R1、R2、R3、a、X1、X2、X3、X4和X5的定义如前所述。已发现化合物的化学式(I)及其盐能够抑制BET家族结构域蛋白与例如乙酰化赖酸残基的结合,因此可能在治疗中发挥作用,例如在治疗自身免疫和炎症性疾病(如类风湿性关节炎)和癌症方面。
  • [EN] BICYCLIC JAK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE JAK BICYCLIQUES ET LEURS UTILISATIONS
    申请人:INSILICO MEDICINE IP LTD
    公开号:WO2020198583A1
    公开(公告)日:2020-10-01
    Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV) and methods of using the compounds, e.g., in the treatment of immune disorders, inflammatory disorders, and cancer.
    本文提供了公式(I)、(II)、(III)和(IV)及其子公式的化合物,其中变量在此处定义。本文还提供了包括公式(I)、(II)、(III)或(IV)化合物的药物组合物,以及使用这些化合物的方法,例如用于治疗免疫紊乱、炎症性疾病和癌症。
  • Piperazines as P2X7 antagonists
    申请人:Betschmann Patrick
    公开号:US20080076924A1
    公开(公告)日:2008-03-27
    Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药,其中取代基如本文所定义,这些化合物可用作治疗剂。
  • PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS
    申请人:Aldous Suzanne C.
    公开号:US20080227782A1
    公开(公告)日:2008-09-18
    This invention is directed to a compound of formula (I): wherein R 1 , R 2 , R 3 and L 1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    本发明涉及一种化合物,其化学式为(I):其中R1,R2,R3和L1如本文所定义,以及包含该化合物的制药组合物,以及使用该化合物治疗过敏和/或炎症性疾病,特别是过敏性鼻炎,哮喘和/或慢性阻塞性肺疾病(COPD)等疾病的用途。
  • [EN] INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] INHIBITEUR D'INDOLÉAMINE-2,3-DIOXYGÉNASE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
    申请人:HINOVA PHARMACEUTICALS INC
    公开号:WO2019149255A1
    公开(公告)日:2019-08-08
    本发明提供了一种式(I)所示的化合物。本发明还涉及含有式(I)化合物的药物组合物以及该化合物在制备吲哚胺-2,3-双加氧酶(IDO)抑制剂类药物中的用途。本发明制备的化合物对IDO蛋白酶具有明显的抑制作用,且在体内代谢稳定。本发明的化合物或其药物组合物可以用于制备IDO抑制剂类药物,也可以用于制备预防和/或治疗具有IDO介导的色酸代谢途径的病理学特征的疾病的药物。
查看更多